UPDATED: Immunovant voluntarily halts studies on sole drug after surprise cholesterol findings, FcRn rival argenx surges
Nearly a year after releasing their first proof-of-concept data, Immunovant’s grand plans for their autoimmune disease antibody have hit a snag.
The Pete Salzmann-led Roivant spinout announced Tuesday that they voluntarily paused dosing on its only two ongoing clinical trials after they were surprised to find that, in one study, patients on the high dose of the drug saw their LDL, commonly known as “bad cholesterol,” rise 60% after 12 weeks. Patients on the low dose of the drug saw a jump of 40%, while the placebo stayed flat.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.